EUVIMEDEUVIMED entdecken
Crossref

Association of urinary LIF levels with disease prognosis and treatment response to methylprednisolone in IgA nephropathy

Lei Zhang, Yaping Dong, Liling Xie, Chun Zhou, Linlin Xu, Shanshan Chao, Yacong An, Hong Zhang, Jicheng Lv, Xujie Zhou, Jing Nie

Nephrology Dialysis Transplantation · 2025

DOI: 10.1093/ndt/gfaf164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, 2025. Verfasst von Lei Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Multi-organ Injury Prevention and Treatment, National Clinical Research Center of Kidney Disease, Department of Nephrology, N…. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Methylprednisolone, Leukemia Inhibitory Factor, Biomarkers. Die Arbeit nennt 34 Literaturangaben. Gefördert von: National High Level Hospital Clinical Research Funding, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Leukemia inhibitory factor (LIF) has been implicated in the production of galactose-deficient immunoglobulin A1 (IgA1) and development of renal fibrosis, and has emerged in several genome-wide association studies as a hotspot gene of IgA nephropathy (IgAN). Therefore, we hypothesize that urinary LIF (uLIF) could predict the renal prognosis and/or treatment response to immunosuppressive therapy in IgAN patients.

Methods

A prognostic study was conducted in a retrospective cohort of 506 biopsy-confirmed IgAN patients. Baseline uLIF concentrations were measured using enzyme-linked immunosorbent assay. Kidney disease progression was defined as a 40% decline in estimated glomerular filtration rate (eGFR), progression to end-stage kidney disease or death due to kidney disease. Additionally, a subcohort derived from the Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) trial was used to investigate the association between changes in uLIF and the response to methylprednisolone therapy in IgAN patients.

Results

Over a median of 35 months of follow-up, 16.6% participants of the prognostic cohort reached the composite kidney progression event. After adjusting for sex, age, eGFR, proteinuria and systolic blood pressure, elevated levels of uLIF/urinary creatinine (uLIF/Cr) were independently associated with an increased risk of kidney progression [per natural log (uLIF/Cr) increment: hazard ratio (HR) 2.16; 1.13–4.13; P for trend 0.019]. In TESTING subcohort, the methylprednisolone group showed a significant greater reduction in uLIF/Cr than the placebo group (41.9% vs 25.4% at 6th month, P = .039; 59.2% vs 19.8% at 12th month, P < .001). The LIF decline group exhibited a significant lower risk of kidney progression compared with LIF non-decline group (adjusted HR 0.431; 0.255–0.730; P for trend 0.002).

Conclusion

This study provides strong initial evidence that uLIF/Cr levels are linked to renal prognosis in IgAN. Moreover, reductions in uLIF/Cr may indicate improved outcomes in patients receiving methylprednisolone. Collectively, our findings suggest uLIF/Cr levels may serve as a valuable biomarker for predicting both renal prognosis and treatment response in IgAN patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, IGAMethylprednisoloneLeukemia Inhibitory FactorBiomarkersHumansMaleFemalePrognosisAdultRetrospective StudiesGlomerular Filtration RateFollow-Up StudiesMiddle AgedDisease Progression

Stichwörter der Autor:innen

IgA nephropathyleukemia inhibitory factormethylprednisolonerenal prognosisurinary LIF

Substanzen

MethylprednisoloneLeukemia Inhibitory FactorBiomarkers

Autor:innen und Institutionen

  • State Key Laboratory of Multi-organ Injury Prevention and Treatment, National Clinical Research Center of Kidney Disease, Department of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Renal Division, Department of Medicine, Peking University First Hospital; Institute of Nephrology, Peking University; Key Laboratory of Renal Disease, Ministry of Health of China; Key Laboratory of CKD Prevention and Tr…
  • Biobank of Peking University First Hospital, Department of Clinical Medical Research, Peking University First Hospital; State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University Health Science Cente…

Förderung

  • National High Level Hospital Clinical Research Funding
  • State Key Laboratory of Vascular Homeostasis and Remodeling
  • Peking University
  • National Natural Science Foundation of China
  • Guangdong Basic and Applied Basic Research Foundation
  • Science and Technology Planning Project of Guangzhou
  • Peking University First Hospital

Zitieren

APA

Zhang, L., Dong, Y., Xie, L., Zhou, C., Xu, L., Chao, S., An, Y., Zhang, H., Lv, J., Zhou, X., & Nie, J. (2025). Association of urinary LIF levels with disease prognosis and treatment response to methylprednisolone in IgA nephropathy. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfaf164

Vancouver

Zhang L, Dong Y, Xie L, Zhou C, Xu L, Chao S, et al. Association of urinary LIF levels with disease prognosis and treatment response to methylprednisolone in IgA nephropathy. Nephrology Dialysis Transplantation. 2025. doi:10.1093/ndt/gfaf164

BibTeX
@article{Zhang2025,
  author = {Zhang, Lei and Dong, Yaping and Xie, Liling and Zhou, Chun and Xu, Linlin and Chao, Shanshan and An, Yacong and Zhang, Hong and Lv, Jicheng and Zhou, Xujie and Nie, Jing},
  title = {Association of urinary LIF levels with disease prognosis and treatment response to methylprednisolone in IgA nephropathy},
  journal = {Nephrology Dialysis Transplantation},
  year = {2025},
  doi = {10.1093/ndt/gfaf164}
}
Kostenlos starten →